Nova Biomedical launches Nova Max Pro Creatinine/eGFR which is CE marked

Waltham, MA – Nova Biomedical announces the launch of Nova Max Pro Creatinine/eGFR Measurement System in all European Union countries. Nova Max Pro is an important new tool for improving renal care by checking kidney function and early detection of kidney disease in out-of-hospital care settings. The easy-to-use Nova Max Pro meter and creatinine biosensor measures blood creatinine and calculates estimated glomerular filtration rate (eGFR), two important indicators of overall kidney function, from a blood sample as small as 1.2 μl of a finger prick in just 30 seconds.

Image credit: Nova Biomedical

the Nova Max Pro The measurement technique is almost identical to that used by a glucose meter Diabetics. Creatinine and estimated glomerular filtration rate (eGFR) results were reported using the CKD-EPI formula (with or without race as a factor) from a small finger blood sample that eliminates the need for venous blood sampling. A patient’s creatinine and eGFR test results are displayed in seconds and can be stored on the meter or connected wirelessly to Bluetooth-enabled apps for review and intervention by healthcare professionals.

Chronic kidney disease (CKD) is a major healthcare crisis and is growing at an exponential rate, rising from 13th to 10th in the World Health Organization’s ranking of the most common cause of death. Kidney disease is often called the “silent killer” because it presents no symptoms and is often diagnosed at a late stage when there are few treatment options other than dialysis, which is very difficult end-stage treatment and very costly for the patient. healthcare system. If caught early, the progression of kidney disease can be prevented or delayed. According to Doug Curley, Nova Sales Product Manager, “Today’s availability of new drugs to delay the progression of kidney disease makes it even more important to detect kidney disease early so treatment can be started before it is too late. NovaMax Pro is a rapid and highly accurate achievement that improves kidney care from By offering screening and early detection of kidney disease to out-of-hospital locations such as pharmacies, clinics, and doctors’ offices.”

Nova Max Pro Creatinine The measurement technology is based on Nova StatSensor Creatinine Technology that has been used in point-of-care applications for over 15 years. Nova technology has been demonstrated in clinical studies in many settings outside of hospitals, including pharmacies, community health centers, imaging centers, clinics, doctors’ offices, and home testing by individuals. One pharmacological study in Spain used the Nova Creatinine/eGFR measurement technique to screen patients who did not have symptoms of CKD but who were either taking potentially nephrotoxic drugs or at risk of developing CKD.1 Forty-four percent of patients tested had an eGFR of less than 60 (the level that indicates kidney disease), highlighting the value of renal disease screening in a pharmacy outpatient setting. Another large university study sponsored by the International Society of Nephrology examined the feasibility of community-based screening of at-risk individuals in three low-income rural countries (LMIC).2 The study demonstrated that it is possible to implement a comprehensive program using POC testing and protocol-based management to improve identification of kidney disease in high-risk patients in these rural areas. Nova Max Creatinine/eGFR is also being used in an ongoing study covering 25 countries and focused on screening asymptomatic but potentially high-risk patients in clinics and doctors’ offices for nephrology. The thesis of this study is that early detection will improve outcomes for patients by allowing for earlier treatment.

About Nova Biomedical
Founded in 1976 and headquartered in Waltham, Massachusetts, Nova Biomedical is a world leader in the development and manufacture of whole blood, point-of-care and critical care analyzers, as well as cell culture monitors for the biotechnology market. Nova uses biosensor technology in products ranging from portable metering devices for self-glucose testing and point-of-care testing to critical care whole blood analyzers designed to measure stats for more than 22 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing more than 20 critical cell culture assays for a wide variety of cell culture applications. Nova employs more than 1,400 people worldwide and has wholly owned subsidiaries in Benelux, Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain and Switzerland. Certified by the International Organization for Standardization, Nova has manufacturing operations in the United States and Taiwan.

  1. Iker Camara-Ramos GE et al. The importance of community pharmacy in the management of chronic kidney disease. Drug dose adjustment and detection of nephrotoxicity. WONCA poster. 2021.
  2. Mehta RL et al. Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: a multi-country feasibility study. PLoS Medicine. 2021; 18: ee1003408

Source link

Related Posts